06855 ASCENTAGE PHARMA GRP INTL

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team.

The English conference call and webcast will be held at 8:00 am EDT / 8:00 pm HKT on March 27, 2025. To access the English conference call, please register in advance to obtain a local or toll-free phone number and your personal pin.   A live webcast of the English conference call will be available on the Ascentage Pharma website at: .

Ascentage will host a Chinese (Mandarin) investor event at 9:30 am HKT on Friday, March 28, 2025 (9:30 pm EDT on Thursday, March 27, 2025), which will also be available simultaneously via conference call and webcast.  To access the Chinese investor event or conference call, please register in advance .

The webcast replay for both conference calls will also be available on the page of the Ascentage Pharma website and will be archived for 30 days.

About Ascentage Pharma

Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol “AAPG” since January 2025.

Contacts

Investor Relations

Hogan Wan, Head of IR and Strategy

Ascentage Pharma



7

Stephanie Carrington

ICR Healthcare



(646) 277-1282 

Media Relations

Sean Leous

ICR Healthcare



(646) 866-4012



EN
12/03/2025

Underlying

06855ASCENTAGE PHARMA GRP INTL

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ASCENTAGE PHARMA GRP INTL

 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

Ascentage Pharma to Participate in Three Upcoming Investor Conferences ROCKVILLE, Md. and SUZHOU, China, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in three upcoming investor conferences. Oppenheimer 36th Annual Healthcare L...

February 23, 2026 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotec...

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 ROCKVILLE, Md. and SUZHOU, China, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 being held...

February 9, 2026 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degr...

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton's tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance f...

February 5, 2026 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma Outlined its Global Innovation Strategy During Presen...

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipelineMultiple global registrational Phase III trials are progressing rapidly ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 68...

January 15, 2026 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Adm...

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global innovative pipeline.Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies. ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; ...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch